Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
McKesson
McKinsey
UBS
Julphar
Fish and Richardson
Cipla
Fuji
Mallinckrodt

Generated: April 26, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,141,581

« Back to Dashboard

Which drugs does patent 7,141,581 protect, and when does it expire?

Patent 7,141,581 protects INLYTA and is included in one NDA.

This patent has seventy-five patent family members in fifty-one countries.
Summary for Patent: 7,141,581
Title:Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
Abstract: Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.
Inventor(s): Bender; Steven (Oceanside, CA), Hu-Lowe; Dana (Encinitas, CA), Shalinsky; David Ray (San Diego, CA)
Assignee: Agouron Pharmaceuticals, Inc. (San Diego, CA)
Application Number:10/639,890
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 7,141,581

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pf Prism Cv INLYTA axitinib TABLET;ORAL 202324-001 Jan 27, 2012 RX Yes No ➤ Sign Up ➤ Sign Up TREATMENT OF RENAL CELL CARCINOMA ➤ Sign Up
Pf Prism Cv INLYTA axitinib TABLET;ORAL 202324-002 Jan 27, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF RENAL CELL CARCINOMA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,141,581

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,884,890 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use ➤ Sign Up
6,891,044 Indazole compounds and pharmaceutical compositions for Inhibiting protein kinases, and methods for their use ➤ Sign Up
6,531,491 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use ➤ Sign Up
7,141,587 Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Queensland Health
QuintilesIMS
Merck
Cantor Fitzgerald
Argus Health
Farmers Insurance
Mallinckrodt
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.